Dundee Securities upgraded AEterna Zentaris (NASDAQ:AEZS TSX:AEZ) to “buy” from “neutral” but kept its price target at $2 (U.S.), based on recent stock weakness and removal of a financing overhang.
Analyst David Martin writes that a financing issue this week should support operations for about 20 months based on an expected burn rate of $2.3 million per month.
“Optimally, AEterna would have completed a license deal for perifosine in ex-U.S. markets, and/or for its AEZS-108 drug, then issue equity at a higher stock price. Nonetheless, the financing eliminates an overhang, as it should provide a funding runway to Phase 3 results for perifosine in multiple myeloma and colorectal cancer. Both trials are expected to report results in the second half of 2011,” he said in a new report.
Disclosure: No positions